We are delighted to introduce you to our new RSC Pharmaceutics Associate Editor Assaf Zinger.
Dr. Assaf Zinger is a leading researcher and educator specializing in nanomedicine and engineering. He is currently an Assistant Professor at the Technion-Israel Institute of Technology and an Adjunct Assistant Professor at the Houston Methodist Academic Institute in Texas, USA. Dr. Zinger’s research focuses on biomimetic nanoparticles, covering various fields from biochemical engineering, where he designs and tests these nanoparticles, to biomedical engineering, where he assesses their effectiveness against conditions like neurodegenerative diseases, brain injuries, and cancers.
“I was drawn to this journal because of its unwavering commitment to publishing ground breaking discoveries in pharmaceutical science and its awesome editorial board. I am hoping that publishing here will not be just about sharing your research; it will be about contributing to the future of medicine.”
Read more about Dr. Zinger here.
Read some of Dr Zinger’s research:
Unleashing the potential of cell biomimetic nanoparticles: Strategies and challenges in their design and fabrication for therapeutic applications
Assaf Zinger
J. Controlled Release, 2023, 358, 591-600
Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles
Assaf Zinger, Manuela Sushnitha, Tomoyuki Naoi, Gherardo Baudo, Enrica De Rosa, Jenny Chang, Ennio Tasciotti and Francesca Taraballi
ACS Nano, 2021, 15, 6326-6339
RSC Pharmaceutics is a new gold open access journal from the Royal Society of Chemistry and publishes research focused on formulating a drug into a medicine, with the intention of achieving controllable drug delivery with high efficacy. This journal is now open for submissions.
Check out our author guidelines for information on our article types or find out more about the advantages of publishing in a Royal Society of Chemistry journal.
Keep up to date with our latest news by following us on LinkedIn. You can also keep informed by signing up to our E-Alerts.